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services. For the majority of UK children, length of stay (LOS) in hospital is brief and
rehydration alone is sufficient. More complex support is sometimes needed in
children with co-morbidities. OBJECTIVES: To compare the hospital burden (LOS
and cost), of children with RVGE and RSV alone, and vulnerable children with
co-morbidities. METHODS: Hospital data were obtained from the CHKS database
between April 1, 2001 and March 31, 2008, where patients, aged 5 years, were
admitted with a primary diagnosis of RVGE or RSV. Patients were categorised into
three groups. G1: a primary diagnosis of RVGE/RSV, G2: controls with a primary
diagnosis of eczema, G3: vulnerable children with a readmission for RVGE/RSV
following a prior admission, within 30 days, with a primary diagnosis of type 1
diabetes (T1D), cystic fibrosis, cancer, or epilepsy. RESULTS: A total of 102,270
patients were selected, group one n101,784 (mean age 0.2 years, LOS 1.9 days, cost
£595), group two n17,420, (mean age 1.1, LOS 1.7, cost £590), and group three
n486, (mean age 1.1, LOS 9.9, cost £3,477). Non-parametric tests showed that
mean age, and hospital LOS were significantly different between groups 1 and 2
(p0.001), while mean age, LOS, and cost were significantly different between
groups 1 and 3 (p0.001), and groups 2 and 3 (p0.001). When adjusted for age,
regression analysis showed that LOS was 5.2 times higher, and cost was 5.8 times
higher in group 3 than group 1. CONCLUSIONS: This study shows that vulnerable
children readmitted to hospital with RVGE/RSV, incur a greater LOS, and subse-
quent cost, compared to other groups. Universal rotavirus vaccination would sub-
stantially benefit vulnerable children through direct or indirect protection and
reduce the healthcare resource use resulting from hospital readmissions.
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OBJECTIVES: Estimating the costs associated with outbreaks and the prevention of
secondary cases of invasive meningococcal disease (IMD) is needed to understand
the true economic burden of IMD. We aimed to review the costs associated with
IMD outbreaks that occur globally. METHODS: Literature searches were conducted
in MEDLINE and EMBASE using medical subject headings and key words, such as
costs, outbreaks, and IMD. Studies were included if they reported the costs associ-
ated with IMD outbreaks and were written in English, French or Spanish. All costs
were converted to USD 2010. RESULTS: A total of 1672 citations were screened and
323 were potentially relevant. Nine studies fulfilled the inclusion criteria and in-
cluded IMD outbreaks with cost data from the US (n4), England, Canada, Guinea,
Burkina Faso and Australia (n1 each) between November 1992 and November
2006. Three outbreaks occurred among high school children, one among boys aged
3-6 years, another among individuals aged 18 years, and two occurred among all
ages. The majority were due to serogroup C (n7/9). The median number of in-
fected per outbreak was 8 (range: 3-2435). The attack rate ranged from 2 per
100,000 to 187 per 100,000, the hospitalization rate from 55.6% to 100%, and the
death rate from 0% to 26%. Containment strategies ranged from targeting all mem-
bers of the school where the outbreak occurred to targeting all students in the
community. The overall average cost per containment was $2,368,135 (USD 2010)
ranging from an average of $296,821 for small containment strategies (n3) to
$3,403,792 for large containment strategies (n6). CONCLUSIONS: IMG outbreaks
were associated with substantial costs. While numerous reports on outbreaks were
identified, few reported on the containment costs. More research in this area is
warranted, particularly to understand the economic value of new vaccines given
that the purpose of vaccination is to prevent potential outbreaks.
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OBJECTIVES: Endometriosis (the presence of endometrial-like tissue outside the
uterus) affects 10% of women of reproductive age and is associated with dysmen-
orrhoea, pain at ovulation, dyspareunia, abnormal bleeding, chronic pelvic pain,
fatigue, and infertility. This study aimed to calculate costs and health-related qual-
ity of life of women with endometriosis-associated symptoms treated in referral
centres. METHODS: A prospective, international, multi-centre questionnaire-
based survey measured costs and health-related quality of life in ambulatory care
and in 12 tertiary care centres in ten countries. The study enrolled women with a
diagnosis of endometriosis and with at least one centre-specific contact related to
endometriosis-associated symptoms in 2008. The main outcome measures in-
cluded health care costs, costs of productivity loss, total costs and quality-adjusted
life years. Predictors of costs were identified using regression analysis. RESULTS:
Data analysis of 909 women (63% response rate) demonstrated that the average
annual total cost per woman was €9,579 (95% CI €8,559-€10,599). Costs of produc-
tivity loss of €6298 per woman were double the health care costs (€3113 per
woman). Health care costs were mainly due to surgery (29%), monitoring tests (19%)
and hospitalization (18%). The cost of medication accounted for 10% of health care
costs. At a prevalence rate of 7%, the annual burden of endometriosis-associated
symptoms ranged from €0.8 billion in Denmark to €50 billion in the United States.
Endometriosis-associated symptoms generated 0.809 quality-adjusted life years
per woman. Decreased quality of life was the most important predictor of direct
health care and total costs. Costs were greater with increasing severity of endome-
triosis, presence of pelvic pain, presence of infertility, and higher number of years
since diagnosis. CONCLUSIONS: The economic burden associated with endome-
triosis is high and is similar to other chronic diseases (diabetes, Crohn’s disease,
rheumatoid arthritis). It arises predominantly from productivity loss, and is pre-
dicted by decreased quality of life.
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OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D vaccine
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and
no vaccination in The Kingdom of Saudi Arabia (KSA). METHODS: A steady state
model with a one-year time horizon was developed to project the impact of vacci-
nation on the incidence of pneumococcal and non-typeable Haemophilus Influenzae
(NTHi) infections in children aged 0-10 years. Data sources: Pneumococcal serotype
distribution is based on 176 invasive S. pneumoniae isolates collected in KSA hospi-
tals in 2005 to 2008. IPD, hospitalised pneumonia and acute otitis media (AOM)
disease incidence rates were based on a study from 12 hospitals in KSA, data from
Turkey and benchmarks with other countries. Vaccines coverage rates for IPD of
79.3 % and 83.9% for PHiD-CV and PCV-13, payer perspective, no herd protection
and a (31) vaccination schedule was assumed. RESULTS: PHiD-CV and PCV-13 are
projected to prevent more cases of invasive disease (724; 749 respectively) and
equal number of pneumonia hospitalizations (510; 510 respectively) compared to
no vaccination. PHiD-CV and PCV-13 are projected to prevent additional myringot-
omies (4783; 2365 respectively) and GP visits due to AOM (170,936; 84,518 respec-
tively) compared to no vaccination strategy. Vaccinating a birth cohort with
PHiD-CV or PCV-13 is expected to generate 8,966; 8,888 more QALYs compared to no
vaccination. At vaccine steady state cost-savings related to disease burden reduc-
tion are $14.1M and $7.6M for PHiD-CV and PCV-13 respectively compared with no
vaccination. Sensitivity analyses indicate that incidence rate of IPD has the biggest
impact on results. CONCLUSIONS: Incremental cost-effectiveness ratios indicate
that both vaccines are cost effective interventions. PHiD-CV dominates PCV-13
because it has a larger potential QALY gain and larger cost offset.
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OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7) was launched as
a Category II vaccine requiring out-of-pocket payment in China in 2008. This study
evaluates the potential economic benefits of introducing a public financed City
Immunization Program (CIP) to pay for PCV7 from a payer perspective. METHODS:
A decision-analytic model was populated with local direct cost and seroprevalence
data from case records of 3 hospitals (1 Children’s Hospital; 2 Comprehensive Hos-
pitals) and literature to estimate the clinical and economic impact of no PCV7
vaccination, PCV7 Category II listing, and PCV7 CIP in the city of Shenzhen. Various
sources of data were used to estimate the primary statistics including age-specific
incidence/mortality of invasive pneumococcal disease (IPD), pneumonia and otitis
media, local patient demographics, and PCV7 efficacy from clinical trial data. The
indirect effect on unvaccinated populations was considered by estimating the re-
duction in adult IPD cases following PCV7 programs published overseas, and was
only applied in the CIP scenario where broad vaccine coverage could be achieved. A
discount rate of 5% was applied, and one-way sensitivity analyses were performed
as well. RESULTS: Under the current setting, the Category II vaccine PCV7 is not
cost-effective due to the private market unit price and low penetration rate. How-
ever, vaccination of 154,721 children under 2 years old from a public financed CIP in
Shenzhen would prevent 18 IPD, 5887 hospitalized pneumonia, 20020 outpatient
pneumonia, and 10669 otitis media cases if indirect effects are included, compared
to no vaccination program. From a payer perspective, a PCV7 CIP would achieve an
ICER of RMB61, 243 (USD9, 141) per QALY versus no vaccination, and dominant
versus Category II. CONCLUSIONS: Results from this study indicate a PCV7 CIP
would be a highly cost-effective intervention from a public payer’s perspective.
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OBJECTIVES: Attention deficit/hyperactivity disorder (ADHD) is a common psychi-
atric disorder with substantial clinical and economic implications. While psycho-
stimulants are first-line pharmacologic treatment, up to 30% of ADHD children
have suboptimal response to psychostimulants and require adjunctive therapy.
Our objective was to analyze the cost-effectiveness of adding an alpha-2A agonist,
A401V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
guanfacine extended release (GXR), to long-acting psychostimulants vs. maintain-
ing existing long-acting psychostimulant monotherapy in children and adoles-
cents with ADHD and suboptimal response to psychostimulant monotherapy.
METHODS: A one-year Markov model was developed from a US third-party payer
perspective. Effectiveness was measured by quality-adjusted life year (QALY). The
model assumed patients transitioned among four health states (normal, mild,
moderate, and severe), defined based on the Clinical Global Impressions-Severity
(CGI-S) scale. Transition probabilities were estimated in an ordered logit model
using patient-level data from a Phase III clinical trial comparing psychostimulants
plus GXR with psychostimulants plus placebo (n461). The model assumed that
patients in moderate or severe states after week eight would discontinue ADHD
treatment and remain in that state. Direct costs included drug wholesale acquisi-
tion costs (WAC) and medical costs, in 2010 US dollars. Health state utilities were
obtained from the literature. Disutilities associated with adverse events were ap-
plied for the first four weeks. One-way sensitivity analyses (SA) were conducted by
varying key model inputs. RESULTS: Adding GXR to existing psychostimulant
monotherapy was associated with an incremental drug cost of $1016 but lower
medical cost of $124, resulting in a total one-year incremental cost of $892. The
addition of GXR led to an incremental QALY of 0.03 and an incremental cost-
effectiveness ratio (ICER) of $31,660/QALY. In one-way SA, ICERs ranged from
$19,723/QALY to $46,631/QALY. CONCLUSIONS: This is the first cost-effectiveness
analysis of psychostimulants with adjunctive medication. Adjunctive therapy of
GXR with psychostimulants is cost-effective based on a willingness-to-pay thresh-
old of $50,000/QALY.
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OBJECTIVES: To determine the cost-effectiveness of TRT with TU (NEBIDO®) com-
pared with placebo for patients with ADAM and DM2, from the Brazilian Private
Healthcare System perspective. METHODS: The study was a cost-effectiveness
analysis based on Markov modeling to estimate costs and consequences of treat-
ments. Epidemiological and efficacy data derived from a critical appraisal of the
scientific literature. Only direct medical costs were considered. If available, costs of
clinical events (CE) were obtained from burden of disease studies. If not, Brazilian
official guidelines were obtained to determine the resources used to treat the CE.
Drug, hospital daily admission rates, procedures and laboratory tests unit costs
were obtained from Brazilian official databases. Costs and benefits were dis-
counted at 5% yearly. Outcomes were expressed as CE avoided. Probability sensi-
tivity analysis (PSA) was conducted to assess model robustness. Life time horizon
was analyzed. RESULTS: The systematic review showed that although the absence
of studies directly evaluating the impact of TU on cardiovascular events, their
favorable influence on cardiovascular disease intermediate markers suggests that
TU may have clinically relevant effect in patients at risk, especially in patients with
metabolic syndrome and/or DM2. The analysis showed higher clinical benefits and
costs for TU. Considering 100 patients, 75.2 and 140.0 CE happen in TU and placebo
arms, respectively. The average time-horizon cost per patient was
R$34,120(€14,896) and R$23,489(€10,255) for TU and placebo, respectively, resulting
in an incremental cost-effectiveness ratio (ICER) of R$16,390/CE avoided (€7,155/CE
avoided). PSA demonstrated that in 83.2% of the simulations TU was more effective
with higher cost and in 16.8% of the simulations TU was dominant compared to
placebo. CONCLUSIONS: Our study demonstrated that TU have clinically relevant
effect in reducing CE being highly cost-effective for ADAM treatment in patients
with DM2 at willingness-to-pay beyond R$19,000/CE avoided (€8,296/CE avoided)
(Brazilian GDP per capita). PSA confirmed this determinist result.
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OBJECTIVES: To estimate values for cost and effectiveness that assess the long-
term efficiency of public health intervention to prevent and correct childhood
obesity. METHODS: A Markov model was developed that takes into account five
diseases strongly associated with obesity: Diabetes Mellitus Type 2, Heart Disease,
Breast Cancer, Colon Cancer and Stroke. Selection of disease was in base of high
rates of morbidity and mortality. In the model, we considered 2 main states: nor-
mal weight (BMI 30 kg/m2) and obese (BMI 30 kg/m2). From them, individuals
can transit to states which representing the 5 diseases and death. Individuals can
transit between normal weight and obese until they reach a certain age (30) when
they can transit to the rest of states. The time horizon was 70 years. A literature
review was performed in order to estimate parameters. The measure of effective-
ness was QALYs and a discount of 3% was applied to costs and utilities. A 2-way
probabilistic sensitivity analysis was made over 2 parameters which define the
intervention: relative risk and cost of intervention. Also, a multivariate and prob-
abilistic sensitivity analysis by 2nd order Monte Carlo (MC) simulations was per-
formed for all parameters. Finally, acceptability curves and the expected value of
perfect information were calculated. RESULTS: If the willingness to pay is € 30,000/
QALY, any intervention that exceeds 1% prevention/correction, incurring in cost
not exceeding € 2 per child and per year should be implemented, because the
probability of hitting the decision is over 90% and does not incur on any opportu-
nity cost. CONCLUSIONS: Long term efficient public health interventions, to pre-
vent/correct childhood obesity, are low cost (not exceeding € 5 per child per year)
due to the effectiveness of interventions, usually lower than 2% of prevention/
correction over non-intervention.
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OBJECTIVES: Dienogest (Visanne ®) is a progestin that has recently been approved
in Europe, Australia and Japan (not in Korea yet) for the treatment of endometriosis
at a dose of 2 mg orally per day. Dienogest provides potent progestogenic effects,
combined with moderate suppression of estrogen levels and has no significant
androgenic, mineralocorticoid, or glucocorticoid activity. The aim of this analysis is
to evaluate cost-effectiveness of dienogest, thereby assessing its eligibility for Na-
tional Health Insurance coverage. METHODS: We carried out a cost-effectiveness
analysis comparing dienogest to leuprolide acetate, a gonodotropin releasing hor-
mone agonist (GnRH-agonist), the current standard treatment for endometriosis
associated pain after laparoscopy. Patients requiring additional treatment because
of pain after laparoscopy were included in the analysis. A third-party-payer per-
spective was taken. The time horizon of analysis was one year. Response to treat-
ment, time horizon of analysis, recurrence rate following discontinuation of
GnRH-a and the incidence of adverse event were considered as major factors for
the decision tree model. An expert survey was conducted to investigate the treat-
ment pattern. Costs of endometriosis were also assessed. In the base case scenario
patients do not receive any sequential treatment after non response or pain recur-
rence. Sensitivity analysis was performed for major variables. RESULTS: At the
base case analysis, dienogest was dominant. Sensitivity analysis showed that the
result was robust for the most variables. Drug cost was the most influential factor
of all. CONCLUSIONS: Dienogest is a cost-effective and cost-saving alternative in
the Korea National Health Insurance context. However the analysis is covering only
one year and long-term clinical data is required to draw a solid conclusion.
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OBJECTIVES: To evaluate the projected health outcomes, costs, and cost-effective-
ness of universal mass vaccination (UMV) with Rotarix™ (GlaxoSmithKline) in Can-
ada compared with no vaccination. METHODS: An age-compartmental, determin-
istic, static Markov cohort model was developed to simulate the disease process of
acute diarrhea events caused by rotavirus infection up to the age of 5 years in
‘monthly’ time cycles, using Canadian demographic and epidemiology data. The
base-case analysis was performed to estimate the direct effects of a UMV program
with two doses of Rotarix™ at 2 and 4 months of age compared to no vaccination,
assuming 90% vaccination coverage. Costs and utilities were discounted at 3.5%.
The efficacy of Rotarix™ was based on published clinical trial results. Model out-
puts include clinical endpoints (deaths, hospitalizations, emergency department
(ED) visits and outpatient visits), and economic measures (net costs per case/death
prevented and quality-adjusted life year gained). Incremental cost-effectiveness
ratios (ICERs) were calculated from the healthcare system perspective, and produc-
tivity loss was reported separately. One-way sensitivity analysis was performed to
evaluate the robustness of the model to variations in the underlying input
parameters. RESULTS:Without vaccination, a Canadian birth cohort of 380,000 can
be expected to have 152,000 rotavirus diarrhea events, 9,000 hospitalizations,
20,849 ED visits, 2,812 nosocomial infections and 6 deaths over 5 years. The base
case results show that a UMV program with Rotarix™ could reduce these events by
69%, 81%, 68%, 76% and 79% respectively over 5 years. At $60 per dose plus $9
administrative fee, the cost per QALY gained over no vaccination is $28,653.
CONCLUSIONS:A UMV program with Rotarix™ is projected to substantially reduce
the health and economic burden of rotavirus infections, and is cost-effective rela-
tive to no vaccination in the Canadian health care system.
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OBJECTIVES: Evaluate the potential benefits of the 10-valent pneumococcal non-
typeable Haemophilus influenzae (NTHi) protein D-conjugated vaccine (PHiD-CV)
and the 13-valent conjugated pneumococcal vaccine (PCV-13) for Argentina.
METHODS: A cohort Markov model was used. The model simulated the impact of
pneumococcal and NTHi related diseases (Invasive Disease (ID), Community Ac-
quired Pneumonia (CAP), and Acute Otitis Media (AOM)) in an argentinean cohort
followed over lifetime. Argentine epidemiology, disease management, and costs
were included in the model. Base case includes conservative assumptions on the
rates of NTHi infections. A 21 vaccination schedule was assumed, with vaccine
coverage of 90% and 2 prices/dose scenarios a) PAHO Revolving Fund 2011 prices, or
b) price parity. Results of the quality adjusted life years gained (QALYs) and future
averted costs, using a 3.5% discount rate, using the health payer perspective, are
presented. RESULTS: The model estimated comparable results between vaccines
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